Surena F. Matin, MD, FACS
Department of Urology, Division of Surgery
About Dr. Surena F. Matin
Dr. Matin received a BS in Biology and Minor in English from Old Dominion University on a full academic scholarship, and attended medical school in New York city at the Cornell University Medical College, now known as the Weill Cornell Medical College. After receiving his M.D., he completed residency in Urology at Cleveland Clinic Foundation, and subsequently stayed for a 1 year research fellowship with a scholarship from the American Foundation of Urologic Disease, followed by a clinical fellowship in Endourology and Minimally Invasive Surgery under the mentorship of Drs. Inderbir Gill, Stevan Streem, and Andrew Novick.
Dr. Matin is currently the Monteleone Family Foundation Distinguished Professor with Tenure in the Department of Urology at MD Anderson Cancer Center, Houston, Texas. He also serves as Medical Director of the MINTOS (Minimally Invasive New Technology in Oncologic Surgery) multidisciplinary collaborative program in the Division of Surgery, which administers the robotic surgery program and has provided free-of-charge, multidisciplinary surgical education to MD Anderson surgery trainees at no cost to the institution since 2006. Dr. Matin has an active clinical practice focusing on the entire spectrum of care for renal cell carcinoma (RCC) and upper urinary tract urothelial cancer (UTUC), ranging from surveillance, endoscopic, laparoscopic, robotic, open and salvage operations for localized and metastatic disease, as well as minimally invasive treatment of adrenal tumors. Dr. Matin has one of the largest UTUC practices in the country. His primary research efforts are based on genomic characterization of UTUC and multiple other lines of research seeking to shed light on this rare cancer, along with clinical research in UTUC and RCC. He actively collaborates with other clinicians, pathologists, radiologists, translational scientists and basic scientists as can be seen in his selected publications.
Present Title & Affiliation
Primary Appointment
Endowed Professor, Monteleone Family Foundation Distinguished Professorship for Research of Bladder and Kidney Cancers, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Tenured Professor, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1994 | Cornell University Medical College, New York City, New York, US, Medicine, Doctor of Medicine (MD) |
| 1990 | Old Dominion University, Norfolk, Virginia, US, Biology (major), English (minor), Bachelor of Science (BS) |
Postgraduate Training
| 2001-2002 | Clinical Fellow, Laparoscopy and Endourology, Cleveland Clinic Foundation, Cleveland, Ohio |
| 2000-2001 | Research Fellow, Tumor Immunology, Cleveland Clinic Foundation, Cleveland, Ohio |
| 1995-2000 | Clinical Resident, Urology, Cleveland Clinic Foundation, Cleveland, Ohio |
| 1994-1995 | Clinical Intern, General Surgery, Cleveland Clinic Foundation, Cleveland, Ohio |
Licenses & Certifications
| 2023 | Mississippi State Board of Medical Licensure |
| 2023 | Oklahoma State Board of Medical Examiners |
| 2023 | Tennessee Board of Medical Examiners |
| 2023 | Louisiana State Board of Medical Examiners |
| 2023 | Arizona Board of Medical Examiners |
| 2023 | Washington State Department of Health |
| 2021 | Florida Board of Medicine |
| 2016 | American College of Surgeons |
| 2003 | American Board of Urology |
| 2002 | Texas Medical Board |
Experience & Service
Other Professional Positions
Collaborator, Patient Mosaic Team, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2021 - Present
Intramural Institutional Committee Activities
Member, von Hippel-Lindau (VHL) Clinical Care Center Collaborative Group, The University of Texas MD Anderson Cancer Center, 2003 - Present
Editorial Activities
Associate Editor, Bladder Cancer Journal, 2020 - Present
Associate Editor, Oncology Section, Urology, 2016 - 2024
Deputy Editor, Oncology Section, Urology, 2015 - 2016
Member, Editorial Board, BJU International, 2012 - 2020
Editor, The Scientific World Journal, 2011 - 2013
Consulting Editor, European Urology, 2011 - Present
Honors & Awards
| 2024 | Top 1% Nationally Ranked Service Provider, HHS Agency for Healthcare Research and Quality: Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG-CAHPS) FY24 |
| 2022 - 2023 | ODU Distinguished Alumni Award, Old Dominion University |
| 2021 | Top 10% provider of those nationally ranked by patients for their delivery of care, MD Anderson Cancer Center, Division of Surgery |
| 2020 | Fellowship Teaching Award, Department of Urology, The University of Texas MD Anderson Cancer Center |
| 2018 | Best of Posters Award, 2018 Annual Meeting, American Urological Association (AUA) |
| 2017 | Best Poster, 2017 EAU Annual Meeting, European Association of Urology (EAU) |
| 2017 | Best of Posters Award, 2017 Annual Meeting, American Urological Association (AUA) |
| 2015 | Best of Posters Award, 2015 Annual Meeting, American Urological Association (AUA) |
| 2013 | SUO Young Investigator Award, Society of Urologic Oncology |
| 2010 | Invited Scholar, Academic Fellowship Exchange, European Association of Urology |
| 2009 | Gold Medal, National Health Information Award, Health and Science Communications Association |
| 2008 | Silver Medal, National Health Information Award, Health and Science Communications Association |
| 2007 | Cum Laude Citation, Radiological Society of North America |
| 2004 - 2005 | Excellence in Teaching Award, Biomedical Engineering Summer Internship Program, The University of Texas MD Anderson Cancer Center |
| 2003 | Best Video in Urology Category, American Society for Reproductive Medicine |
| 2001 - 2002 | Scholars in Urology Award, Pfizer |
| 2000 - 2001 | Scholar Award, American Foundation for Urologic Disease |
| 2000 | Bruce H. Stewart Award for Humanistic Medicine, Cleveland Clinic Foundation |
| 1986 - 1990 | Dominion Scholar, Old Dominion University |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Universal Testing Programs: Genetic Testing in the Upper Tract Urothelial Carcinoma Population. Invited. 9th Annual Hereditary Cancer Symposium for Health Care Providers. Houston, Texas, US.
- 2021. Speaker: “Single Port Robotic Assisted Surgery in Kidney Cancer”. Conference. Speaker: “Single Port Robotic Assisted Surgery in Kidney Cancer”. Houston, TX, US.
Regional Presentations
- 2025. Renal Preservation Strategies for Upper Tract Urothelial Carcinoma. Invited. University of Texas 3rd Annual Christopher G. Wood Advances in Urologic Oncology Symposium. Austin, Texas, US.
- 2025. Case Discussions: Upper Tract Urothelial Carcinoma. Panelist. University of Texas 3rd Annual Christopher G. Wood Advances in Urologic Oncology Symposium. Austin, Texas, US.
- 2024. When Should Neoadjuvant Treatment be Considered for Bulky Tumors and IVC Thrombi?. Invited. University of Texas Christopher G. Wood Advances in Urologic Oncology Symposium. Austin, Texas, US.
- 2024. Renal (Advanced) Rapid Cases. Invited. University of Texas Christopher G. Wood Advances in Urologic Oncology Symposium. Austin, Texas, US.
- 2023. Management of UTUC: Considerations for Ureteral Disease. Invited. UCI Urology Grandest Rounds. Irvine, California, US.
- 2023. Upper Tract Tumors: Endoscopic Management. Invited. Jon A. Kaswick, MD Urology Symposium. Indian Wells, California, US.
- 2023. Debate: Role of Neoadjuvant Therapy and Lymph Node Dissection. Invited. Jon A. Kaswick, MD Urology Symposium. Indian Wells, California, US.
- 2023. Reconstruction for Ureteral Disease. Invited. Jon A. Kaswick, MD Urology Symposium. Indian Wells, California, US.
- 2023. Panel Discussion and Resident-Led Case Presentations. Invited. Jon A. Kaswick, MD Urology Symposium. Indian Wells, California, US.
- 2023. Renal Localized Case Surveillance. Conference. Renal Localized Case Surveillance. Austin, TX, US.
National Presentations
- 2026. Decision Making in the Management of Small Renal Cell Tumors. Conference. 22nd Oncology Updates: Advances and Controversies. Steamboat Springs, Colorado, US.
- 2025. IP12: Bladder Cancer: Upper Tract Transitional Cell Carcinoma. Poster. AUA Annual Meeting 2025. Las Vegas, Nevada, US.
- 2025. Considerations for Special Populations: Conservative management of upper tract. Invited. Advanced Urologic Cancer Consensus Conference (AUC3). Miami, Florida, US.
- 2024. Presentations and Case Discussion: Management of Localized Renal Masses in Complex Clinical Situations. Panelist. 103rd Annual Meeting of the South Central Section of the AUA. Colorado Springs, Colorado, US.
- 2024. MP38: Bladder Cancer: Upper Tract Transitional Cell Carcinoma. Poster. AUA Annual Meeting 2024. San Antonio, Texas, US.
- 2024. Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management. Conference. AUA Annual Meeting 2024. San Antonio, Texas, US.
- 2023. Urothelial Cancer Session. Invited. 24th Annual Meeting of the Society of Urologic Oncology. Washington, D.C, District of Columbia, US.
- 2023. Speaker: Late-Breaking Abstracts II - Cancer. Conference. AUA Annual Meeting 2023. Chicago, IL, US.
- 2023. Moderator: Panel Discussion: Management of Upper Tract Urothelial Carcinoma. Conference. AUA Annual Meeting 2023. Chicago, IL, US.
- 2023. Upper Tract UC: Is It a Different Disease?. Conference. New York GU 2023. New York City, NY, US.
- 2022. Speaker: Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach. Conference. Mid-Atlantic Section of the AUA Annual Meeting 2022. New Orleans, LA, US.
- 2022. Monthly Oncology Tumor Boards: Treatment of Patients with Kidney Cancer. Conference. Monthly Oncology Tumor Boards: Treatment of Patients with Kidney Cancer, US.
- 2022. Speaker: Management of Upper Tract Disease Without Nephroureterectomy. Conference. SCS-AUA 2022 Annual Meeting. Coronado, CA, US.
- 2022. Speaker: Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management. Conference. AUA Annual Meeting 2022. New Orleans, LA, US.
- 2022. Abstract: Interim Results from a Phase 1b Clinical Trial Evaluating Tolerability and Activity of FGFR Inhibition in Localized Upper Tract Urothelial Carcinoma (UTUC). Conference. AUA Annual Meeting 2022. New Orleans, LA, US.
- 2022. Poster: Universal Germline Genetic Testing of Patients with Newly Diagnosed Upper Tract Urothelial Carcinoma: An Interim Analysis. Conference. AUA Annual Meeting 2022. New Orleans, LA, US.
- 2022. Podium: enotype-Phenotype Characterization of Lynch Syndrome Associated Upper Tract Urothelial Carcinoma (UTUC). Conference. AUA Annual Meeting 2022. New Orleans, LA, US.
- 2022. Endoscopic Management of Low-Grade Upper-Tract Urothelial Carcinoma. Conference. 2022 ASCO Genitourinary Cancers Symposium Program. San Francisco, CA, US.
- 2021. Poster: Durability of Response to Chemoablative Treatment of Low-Grade Upper Tract Urothelial Carcinoma with a Mithomycin-Containing Reverse Thermal Hydrogel: Final Results of the Olympus Trial. Conference. SUO Annual Meeting 2021. Orlando, FL, US.
- 2021. Upper Tract Urothelial Carcinoma: Translational Updates. Conference. Annual Meeting of Puerto Rico Urological Association. San Juan, PR, US.
- 2021. The New Bosniak System and Current Concepts in Management of. Conference. Annual Meeting of Puerto Rico Urological Association. San Juan, PR, US.
- 2021. Speaker: Surgical Techniques: Surgery for Upper Tract Urothelial Carcinoma. Conference. AUA Annual Meeting 2021, MD, US.
- 2021. Speaker: Advances in Early-Stage Urothelial Cancer: Expert Guidance for a New Treatment Algorithm. Conference. AUA Annual Meeting 2021, MD, US.
- 2021. Speaker: “Advances in Early-Stage Urothelial Cancer: Expert Guidance for a New Treatment Algorithm”. Conference. CCO-AUA Symposium on UTUC. Las Vegas, NV, US.
- 2021. Speaker: Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management. Conference. AUA Annual Meeting 2021, MD, US.
- 2021. Virtual Speaker: Everyday Cases in Low Risk Upper Tract Urothelial Carcinoma. Conference. Virtual Speaker: Everyday Cases in Low Risk Upper Tract Urothelial Carcinoma, US.
- 2021. Speaker: Novel and multimodality management strategies for localized UTUC. Conference. Identification of Current and Needed Clinical Trials for Novel Therapeutics: A Johns Hopkins Greenberg Bladder Cancer Institute/AUA Translational Research Collaboration, MD, US.
International Presentations
- 2025. Clinical and translational updates in UTUC. Invited. MDACC International GU Cancer Summit and Urologic Endoscopic Surgery Advancement Conference. Kaohsiung, TW.
- 2025. Surgical strategies for complex robotic partial nephrectomy. Invited. MDACC International GU Cancer Summit and Urologic Endoscopic Surgery Advancement Conference. Kaohsiung, TW.
- 2025. Urothelial Carcinoma - German Focus. Panelist. Global Advancements in Urothelial Carcinoma (webinar education series), US.
- 2023. Is it possible to do partial nephrectomy in T1b/T2 RCC?. Invited. Taiwan Urological Association and MD Anderson Cancer Center International Uro-Oncological Conference. Taichung City, TW.
- 2023. Robotic RCC Challenging Case Debate. Invited. Taiwan Urological Association and MD Anderson Cancer Center International Uro-Oncological Conference. Taichung City, TW.
- 2023. UTUC: review of new AUA guidelines. Invited. SUO/YUO Fall Webinar Series, US.
- 2022. Role of Cytoreductive Nephrectomy in the Era of Immunotherapy. Conference. Role of Cytoreductive Nephrectomy in the Era of Immunotherapy, CL.
- 2022. Locally Advanced Kidney Cancer - Management in 2022. Conference. Locally Advanced Kidney Cancer - Management in 2022, CL.
- 2022. •Active surveillance for the small renal mass: selection, methods, outcomes. Conference. •Active surveillance for the small renal mass: selection, methods, outcomes, LY.
- 2022. Non-Muscle Invasive Bladder Cancer. Conference. Non-Muscle Invasive Bladder Cancer, LY.
- 2022. Speaker: •Active surveillance for the small renal mass: selection, methods, outcomes. Conference. 1st Libyan Multidisciplinary Conference on Urological Cancers (LMUC22). Misurata, LY.
- 2022. Speaker: Non-Muscle Invasive Bladder Cancer. Conference. 1st Libyan Multidisciplinary Conference on Urological Cancers (LMUC22). Misurata, LY.
- 2022. Lecture: Cryoablation of renal cell masses. Conference. 1st Libyan Multidisciplinary Conference on Urological Cancers (LMUC22). Misurata, LY.
- 2022. Virtual Speaker: Active Surveillance in Renal Masses: State of the art. Conference. Annual Course of the Chilean National Society 2022. Satiago, CL.
- 2021. Update on UTUC. Conference. 13th PMCC Uro-Oncology Dialogue Virtual Meeting 2021. Toronto, CA.
Formal Peers
- 2016. Risk Stratified Approach to Treatment of Upper Tract Urothelial Carcinoma. Visiting. Hangzhou, CN.
- 2013. Diagnostic Imaging Quality Improvement. Houston, Texas, US.
- 2013. Urologic Ultrasound. Houston, Texas, US.
- 2010. Neoadjuvant and Adjuvant Therapies for RCC: Clinical and Translational Opportunities, Joint Symposium on Cancer Research. Invited. Barretos, BR.
- 2010. Role of Robotic Cystectomy and PLND: What are the Results and is There a Benefit?, Joint Symposium on Cancer Research. Invited. Barretos, BR.
- 2010. Role of Lymphadenectomy for RCC and Upper Tract Urothelial Carcinoma, Joint Symposium on Cancer Research. Invited. Barretos, BR.
- 2010. Minimally Invasive Surgery-Perspectives in Oncology, Joint Symposium on Cancer Research. Invited. Barretos, BR.
- 2010. Contemporary Strategies for Management of High Risk Upper Tract Urothelial Carcinoma. Invited. Madrid, Spain, ES.
- 2010. Contemporary Strategies for Management of High Risk Upper Tract Urothelial Carcinoma. Invited. Padua, Italy, IT.
- 2010. Laparoscopic and Robotic Partial Nephrectomy. Invited. Munich, Germany, DE.
- 2010. The Role of Systemic Therapy for Treatment of Metastatic Kidney Cancer with the Primary in Place. Invited. Bratislava, Slovakia, SK.
- 2009. Invited Speaker, Development and Integration of a Minimally Invasive and Robotic Surgical Program at a Major Cancer Center. Visiting, US.
- 2007. Visiting Professor. Visiting. Las Condes, CL.
- 2005. Visiting Professor. Visiting. Chengdu, CN.
- 2004. Visiting Professor. Visiting. Hamilton, CA.
- 2003. Visiting Professor. Visiting. Cape Town, ZA.
Grant & Contract Support
| Date: | 2026 - Present |
| Title: | A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC) |
| Funding Source: | Urogen |
| Role: | Co-I |
| ID: | 2025-1396 |
| Date: | 2026 - Present |
| Title: | A Phase 1/2, Single-arm, Open-Label Trial to Evaluate the Safety and Efficacy of Nadofaragene Firadenovec Instilled to the Renal Pelvis in Adult Subjects with Low-grade Upper Tract Urothelial Carcinoma (LG-UTUC) |
| Funding Source: | Ferring |
| Role: | PI |
| ID: | 2025-0515 |
Selected Publications
Peer-Reviewed Articles
- Ratcliff CG, Semelsberger R, Matin SF, Tannir NM, Jonasch E, Pisters LL, Cohen L. Sex differences in the association of emotional approach coping with stress and quality of life among patients with renal cell carcinoma. Palliat Support Care 24:e49, 2026. e-Pub 2026. PMID: 41612823.
- Lee MS, Hensley PJ, Igel D, Li R, Clark RK, Bingham N, Pallauf M, Thapa P, Boorjian SA, Raman JD, Singla N, Coleman J, Margulis V, Spiess PE, Matin SF, Potretzke AM. Oncologic and survival outcomes in patients undergoing radical nephroureterectomy with preoperative or iatrogenic dialysis dependence. Urol Oncol 43(11):662.e9-662.e15, 2025. e-Pub 2025. PMID: 40754548.
- Labbate C, Igel DA, Saporito D, Adibi M, Mork M, Ozambela M, Vilar-Sanchez E, Guo C, Czerniak B, Jonasch E, Matin SF. Genotype-Phenotype Characterization of Lynch Syndrome-associated Upper Tract Urothelial Carcinoma. Eur Urol Oncol, 2025. e-Pub 2025. PMID: 41176509.
- Katims, A, Tin, AL, Assel, M, Hensley, PJ, Li, R, Margulis, V, Matin, S, Pallauf, M, Clark, RK, Raman, JD, Singla, N, Spiess, PE, Coleman, JA. Predictors and Patterns of Nonurothelial Recurrence after Nephroureterectomy for Upper Tract Urothelial Carcinoma (UCAN Collaboration). Journal of Urology 214(4):407-413, 2025. e-Pub 2025. PMID: 40526449.
- Moghaddam FS, Ghoreifi A, Sayyid RK, Wu Z, Abdollah F, Antonelli A, Eun DD, Guo S, Hung AJ, Ma L, Margulis V, Matin SF, Mehrazin R, Porter J, Potretzke A, Pradere B, Roupret M, Seisen T, Shariat SF, Simone G, Stein RJ, Wang L, Wu J, Xylinas E, Yao L, Zargar H, Autorino R, Cacciamani GE, Djaladat H. A structured training curriculum for robot-assisted radical nephroureterectomy: a Delphi consensus study. BJU Int 136(6):1114-1120, 2025. e-Pub 2025. PMID: 40960222.
- Herrera-Caceres JO, Wettstein M, Matin SF, Labbate C, Potretzke A, Rodriguez R, Singla N, Pallauf M, Huang W, Nagpal S, Kleinmann N, Shvero A, Small A, Green B, Linehan J, Choe J, Shah O, Rai A, Kaimakliotis H, Tachibana I, Canes D, Perecman A, Raman JD. Outcomes of endoscopic management for upper tract urothelial carcinoma: A multi-center international cohort analysis. Urol Oncol 43(12):697.e1-697.e9, 2025. e-Pub 2025. PMID: 40858459.
- Lehner K, Li R, Hensley PJ, Clark RK, Pallauf M, Katims A, Bingham N, Thapa P, Boorjian SA, Raman JD, Singla N, Coleman J, Margulis V, Spiess PE, Matin SF, Potretzke AM. Smoking is Associated with Poorer Survival Outcomes Following Nephroureterectomy for Upper Tract Urothelial Cancer. Urology, 2025. e-Pub 2025. PMID: 40848880.
- Ghasemzadeh A, Abel EJ, Karam JA, Spiess PE, Peyton CC, Manley BJ, Sirard RB, Robertson N, Ellis EE, Cotta BH, Patel KR, Nicaise E, Jani A, Sexton WJ, Patil D, Allen GO, Matin SF, Master VA, Shapiro DD. Risk Factors for First-Year Recurrence in Patients With Synchronous Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy and Complete Metastasectomy. J Urol:101097JU0000000000004705, 2025. e-Pub 2025. PMID: 40763351.
- Abdelsalam ME, Awad A, Bassett RL, Lu T, Irwin D, Shah KY, Odisio BC, Habibollahi P, Karam JA, Matin SF, Ahrar K. Technique and Outcomes of Radiofrequency Ablation of Biopsy-Proven 3–4 cm T1a Renal Cell Carcinoma. Biomedicines 13(6), 2025. e-Pub 2025. PMID: 40564015.
- Lange S, Reinhardt A, Igel D, Labbate C, Adibi M, Kundu S, Matin SF. The Upper TRACT Endometry Score. J Urol 213(4):467-474, 2025. e-Pub 2025. PMID: 39666938.
- Pierorazio, P, Kleinmann, N, Shabsigh, A, Hu, B, Raman, JD, Kaimakliotis, H, Sankin, A, Singla, N, Meads, A, Burger, B, Raju, S, Louie, MJ, Chamie, K, Weizer, AZ, Schoenberg, M, Godoy, G, Lerner, SP, Gore, JL, Hubosky, SG, Quek, M, Stern, JM, Matin, S, Weight, C, Smith, AB, Coleman, JA, Linehan, J, Humphreys, MR, Lifshitz, D, Verni, M, McLaren, RH, Nielsen, ME, Scherr, DS, Pak, R. Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel. Journal of Urology 213(3):313-321, 2025. e-Pub 2025. PMID: 39561384.
- Woldu SL, Igel D, Johnson B, Murray KS, Miyagi H, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin MA, Heidenberg D, Humphreys M, Ghodoussipour S, Quek ML, O'Donnell M, Eisner BH, Matin SF, Feldman AS, Lotan Y. Durability of response of UGN-101: Longitudinal follow up of multicenter study. Urol Oncol, 2025. e-Pub 2025. PMID: 39837708.
- Yu A, Hensley PJ, Huelster HL, Martin A, Potrezke A, Pham J, Raman JD, Pallauf M, Singla N, Katims A, Coleman J, Margulis V, Matin SF, Spiess PE. Response to neoadjuvant chemotherapy leads to better survival outcomes in upper tract urothelial carcinoma. BJU Int 135(6):994-999, 2025. e-Pub 2025. PMID: 39825642.
- Fields BC, Newhook TE, Lillemoe HA, Qiao W, Karam JA, Matin SF, Meyer LA, Tzeng CD. 5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Randomized Clinical Trial Protocol. Adv Cancer Educ Qual Improv 1(1), 2025. e-Pub 2025. PMID: 40583965.
- Carpinito GP, Gerald T, Hensley PJ, Martin AJ, Pallauf M, Pham J, Li R, Potretzke AM, Spiess PE, Singla N, Raman JD, Coleman J, Matin SF, Margulis V. The role of neoadjuvant systemic therapy for high grade upper tract urothelial carcinoma: Results from the upper tract collaborative network (UCAN). Urol Oncol, 2024. e-Pub 2024. PMID: 39721824.
- Hensley PJ, Labbate C, Zganjar A, Howard J, Huelster H, Durdin T, Pham J, Xiao L, Pallauf M, Lombardo K, Glezerman I, Singla N, Raman JD, Coleman J, Spiess PE, Margulis V, Potretzke AM, Matin SF. Development and Validation of a Multivariable Nomogram Predictive of Post-Nephroureterectomy Renal Function. Eur Urol Oncol 7(6):1313-1319, 2024. e-Pub 2024. PMID: 38307832.
- Zhao J, Shen Y, Guo M, Matin SF, Hansel DE, Guo CC. Diagnostic accuracy of upper tract urothelial carcinoma using biopsy, urinary cytology, and nephroureterectomy specimens a tertiary cancer center experience. Am J Clin Pathol 162(5):492-499, 2024. e-Pub 2024. PMID: 38860463.
- Abdelsalam ME, Lu T, Baiomy A, Awad A, Odisio BC, Habibollahi P, Irwin D, Karam JA, Matin SF, Stafford J, Ahrar K. Magnetic resonance imaging–guided renal biopsy shows high safety and diagnostic yield. Eur Radiol 34(9):5551-5560, 2024. e-Pub 2024. PMID: 38400904.
- Matin, S, Adibi, M, Shah, AY, Alhalabi, O, Corn, P, Guo, C, Amirtharaj, R, Xiao, L, Lange, S, Duose, D, Wang, S, Pal, S, Campbell, M. Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma. Journal of Urology 211(6):784-792, 2024. e-Pub 2024. PMID: 38573872.
- Abdelsalam, ME, Mecci, N, Awad, A, Bassett Jr, R, Odisio, BC, Habibollahi, P, Lu, T, Irwin, DC, Karam, JA, Matin, S, Ahrar, K. Magnetic-Resonance-Imaging-Guided Cryoablation for Solitary-Biopsy-Proven Renal Cell Carcinoma. Cancers 16(10), 2024. e-Pub 2024. PMID: 38791894.
- Abel EJ, Master VA, Spiess PE, Raman JD, Shapiro DD, Sexton WJ, Zemp L, Patil D, Lauer K, Allen GO, Matin SF, Karam JA. The Selection for Cytoreductive Nephrectomy (SCREEN) Score. Eur Urol Oncol 7(2):266-274, 2024. e-Pub 2024. PMID: 37442673.
- Ozambela M, McCormick B, Rudzinski JK, Pieretti AC, González GM, Meissner M, Papadopoulos JN, Adibi M, Matin SF, Dahmen AS, Spiess, PE, Pettaway CA. Robotic or open superficial inguinal lymph node dissection as staging procedures for clinically node negative high risk penile cancer. Urologic Oncology: Seminars and Original Investigations 42(4):120.e1-120.e9, 2024. e-Pub 2024. PMID: 38388244.
- Singh, J, Wang, L, Smith III, T, Graber, WJ, Matin, S, Pisters, LL, Lenaine Westney, O. Ileal Interposition for Ureteral Reconstruction Following Treatment for Abdominopelvic Malignancy. Urology 183:215-220, 2024. e-Pub 2024. PMID: 37802194.
- Jacob JM, Woldu SL, Linehan J, Labbate C, Rose KM, Sexton WJ, Tachibana I, Kaimakliotis H, Nieder A, Bjurlin MA, Humphreys M, Ghodoussipour SB, Quek ML, Johnson B, O'Donnell M, Eisner BH, Feldman AS, Murray KS, Matin SF, Lotan Y, Dickstein RJ. First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors. Urol Oncol 42(1):20.e17-20.e23, 2024. e-Pub 2024. PMID: 37517898.
- Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CG. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun 14(1), 2023. e-Pub 2023. PMID: 37164948.
- Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol 6(6):611-620, 2023. e-Pub 2023. PMID: 37833193.
- Esdaille AR, Karam JA, Master VA, Spiess PE, Raman JD, Sharma P, Shapiro DD, Das A, Sexton WJ, Zemp L, Patil D, Allen GO, Matin SF, Wood CG, Abel EJ. Contemporary Patients Have Better Perioperative Outcomes Following Cytoreductive Nephrectomy: A Multi-institutional Analysis of 1272 Consecutive Patients. Urology 182:168-174, 2023. e-Pub 2023. PMID: 37690543.
- Abdelsalam ME, Hudspeth TN, Leonards L, Kusin SB, Buckley JR, Bassett R, Awad A, Karam JA, Matin SF, Lu T, Ahrar K. Effectiveness of Thermal Ablation for Renal Cell Carcinoma after Prior Partial Nephrectomy. Eur Urol Open Sci 57:45-50, 2023. e-Pub 2023. PMID: 38020520.
- Linehan J, Gottlieb J, Woldu SL, Labbate C, Rose K, Sexton W, Kaimakliotis H, Jacob J, Dickstein R, Nieder A, Bjurlin M, Humphreys M, Ghodoussipor S, Quek M, O'Donnell M, Eisner BH, Feldman AS, Matin SF, Lotan Y, Murray KS. Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes. Eur Urol Focus 9(6):1052-1058, 2023. e-Pub 2023. PMID: 37263827.
- Kaimakliotis HZ, Tachibana I, Woldu S, Labbate C, Jacob J, Murray K, Rose K, Sexton W, Dickstein R, Linehan J, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner BH, Matin SF, Lotan Y, Feldman AS. The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma. Urol Oncol 41(9):387.e1-387.e7, 2023. e-Pub 2023. PMID: 37246135.
- Rose KM, Murray KS, Labbate C, Woldu S, Linehan J, Jacob J, Kaimakliotis H, Dickstein R, Feldman A, Matin SF, Lotan Y, Humphreys MR, Sexton WJ. Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease. Eur Urol Focus 9(5):807-812, 2023. e-Pub 2023. PMID: 37059620.
- Linehan J, Gottlieb J, Woldu SL, Labbate C, Rose K, Sexton W, Kaimakliotis H, Jacob J, Dickstein R, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner BH, Feldman AS, Matin SF, Lotan Y, Murray KS. Corrigendum to "Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes" [Eur. Urol. Focus (2023)]. Eur Urol Focus. e-Pub 2023. PMID: 37640582.
- Coleman JA, Clark PE, Bixler BR, Buckley DI, Chang SS, Chou R, Hoffman-Censits J, Kulkarni GS, Matin SF, Pierorazio PM, Potretzke AM, Psutka SP, Raman JD, Smith AB, Smith L. Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline. J Urol 209(6):1071-1081, 2023. e-Pub 2023. PMID: 37096584.
- Labbate C, Woldu S, Murray K, Rose K, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin M, Humphreys M, Ghodoussipor S, Quek M, O'Donnell M, Eisner B, Feldman A, Lotan Y, Matin SF. Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma. J Urol 209(5):872-881, 2023. e-Pub 2023. PMID: 36657029.
- Shapiro DD, Karam JA, Zemp L, Master VA, Sexton WJ, Ghasemzadeh A, Schmeusser BN, Davaro F, Peak T, Patil D, Matin SF, Spiess PE, Abel EJ. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 50:43-46, 2023. e-Pub 2023. PMID: 36861106.
- Woldu SL, Labbate C, Murray KS, Rose K, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin MA, Humphreys M, Ghodoussipour S, Quek ML, O'Donnell M, Eisner BH, Feldman AS, Matin SF, Lotan Y. Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes. Urol Oncol 41(3):147.e15-147.e21, 2023. e-Pub 2023. PMID: 36424224.
- Lange S, Calleris G, Matin SF, Rouprêt M. Optimizing Lymph Node Dissection at the Time of Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma. Eur Urol Focus 9(2):280-282, 2023. e-Pub 2023. PMID: 36642620.
- Abdelsalam ME, Awad A, Baiomy A, Irwin D, Karam JA, Matin SF, Sheth RA, Habibollahi P, Odisio BC, Lu T, Ahrar K. Outcomes of Radiofrequency Ablation for Solitary T1a Renal Cell Carcinoma. Cancers (Basel) 15(3), 2023. e-Pub 2023. PMID: 36765867.
- Lange SM, Matin SF. EDITORIAL COMMENT. Urology 172:155-156, 2023. e-Pub 2023. PMID: 36773986.
- Labbate CV, Hensley PJ, Miest TS, Qiao W, Adibi M, Shah AY, Chery L, Papadopoulos J, Siefker-Radtke AO, Gao J, Guo CC, Czerniak BA, Navai N, Kamat AM, Dinney CP, Campbell MT, Matin SF. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol 40(10):454.e17-454.e23, 2022. e-Pub 2022. PMID: 35961847.
- Westerman ME, Bree KK, Msaouel P, Kukreja JB, Mantaring C, Rukundo I, Gonzalez MG, Gregg JR, Casteel KN, Matin SF. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis. J Urol 208(4):886-895, 2022. e-Pub 2022. PMID: 36082549.
- Pieretti AC, Ozambela M, Westerman ME, Nogueras-Gonzalez GM, Segarra LA, Zacharias NM, Vaporciyan A, Hofstetter W, Huynh T, Aldousari S, Matin SF, Karam JA. Predictors of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus. Clin Genitourin Cancer 20(4):e330-e338, 2022. e-Pub 2022. PMID: 35279419.
- Karam JA, Puligandla M, Flaherty KT, Uzzo RG, Matin SF, Pins MR, Wood CG, Kane C, Jewett MAS, Kim SE, Dutcher JP, DiPaola RS, Haas NB. Adjuvant therapy in patients with sarcomatoid RCC: Post hoc analysis from ECOG-ACRIN E2805. BJU Int 129(6):718-722, 2022. e-Pub 2022. PMID: 34480522.
- De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int 129(5):610-620, 2022. e-Pub 2022. PMID: 34228889.
- Westerman ME, Yevich SM, Dori Y, Ward JF, Pisters LL, Karam JA, Wood CG, Avritscher R, Matin SF. Lymphangioembolization for iatrogenic chylous ascites after retroperitoneal urological surgery. BJU Int 129(5):585-587, 2022. e-Pub 2022. PMID: 34962705.
- Adibi M, McCormick B, Economides MP, Petros F, Xiao L, Guo C, Shah A, Kamat AM, Dinney C, Navai N, Gao J, Siefker-Radtke A, Matin SF, Campbell MT. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer 20(2):176-182, 2022. e-Pub 2022. PMID: 35039231.
- Matin SF, Pierorazio PM, Kleinmann N, Gore JL, Shabsigh A, Hu B, Chamie K, Godoy G, Hubosky SG, Rivera M, O'Donnell M, Quek M, Raman JD, Knoedler JJ, Scherr D, Weight C, Weizer A, Woods M, Kaimakliotis H, Smith AB, Linehan J, Coleman J, Humphreys MR, Pak R, Lifshitz D, Verni M, Klein I, Konorty M, Strauss-Ayali D, Hakim G, Seltzer E, Schoenberg M, Lerner SP. Reply by Authors. J Urol 207(4):788, 2022. e-Pub 2022. PMID: 34985341.
- Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke AO, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AY. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass 3(1):37-44, 2022. e-Pub 2022. PMID: 35475152.
- Pieretti AC, Shapiro DD, Westerman ME, Hwang H, Wang X, Segarra LA, Campbell MT, Tannir NM, Jonasch E, Matin SF, Wood CG, Karam JA. Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urol Oncol 39(12):837.e9-837.e17, 2021. e-Pub 2021. PMID: 34551888.
- Matin SF, Pierorazio PM, Kleinmann N, Gore JL, Shabsigh A, Hu B, Chamie K, Godoy G, Hubosky SG, Rivera M, O'Donnell M, Quek M, Raman JD, Knoedler JJ, Scherr D, Weight C, Weizer A, Woods M, Kaimakliotis H, Smith AB, Linehan J, Coleman J, Humphreys MR, Pak R, Lifshitz D, Verni M, Klein I, Konorty M, Strauss-Ayali D, Hakim G, Seltzer E, Schoenberg M, Lerner SP. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. J Urol:101097JU0000000000002350. e-Pub 2021. PMID: 34915741.
- Pieretti AC, Westerman ME, Childs A, Millward N, Shapiro DD, Sircar K, Rao P, Jonasch E, Campbell MT, Tannir NM, Matin SF, Wood CG, Karam JA. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol 39(11):790.e17-790.e23, 2021. e-Pub 2021. PMID: 34301458.
- Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo AB, Allison JP, Yadav SS, Sharma P. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun 12(1):6375, 2021. e-Pub 2021. PMID: 34737281.
- Ghandour RA, Freifeld Y, Cheaib J, Singla N, Meng X, Kenigsberg A, Bagrodia A, Woldu S, Hoffman-Censits J, Enikeev D, Rapoport L, Petros FG, Raman JD, Pierorazio PM, Matin SF, Margulis V. Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma. Urol Oncol 39(11):788.e15-788.e21, 2021. e-Pub 2021. PMID: 34330655.
- Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke A, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AY. Multimodal kidney‐preserving approach in localised and locally advanced high‐risk upper tract urothelial carcinoma. BJUI Compass. e-Pub 2021.
- Altok M, Chapin BF, Matin SF, Achim MF, Gregg JR, Davis JW. Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase. Urology 155:144-151, 2021. e-Pub 2021. PMID: 33676955.
- Miest T, Khanna A, Sharma V, Hensley PJ, Campbell R, Thapa P, Zganjar A, Tollefson MK, Thompson RH, Frank I, Karnes RJ, Potretzke A, Matin SF, Murthy PB, Haber GP, Lee B, Boorjian SA. Development and Validation of a Risk-Adapted Scoring Model for Metachronous Upper Tract Urothelial Carcinoma Following Radical Cystectomy. J Urol:101097JU0000000000002211. e-Pub 2021. PMID: 34547921.
- Pisters PW, Ranasinghe W, Wei W, Wood CG, Matin SF, Ward JF, Pisters LL. Long-term renal functional outcomes following ureteroureterostomy performed during multi-organ resection for non-urothelial cancers. BJUI Compass 2(5):348-354, 2021. e-Pub 2021. PMID: 35474874.
- D'Andrea, D, Matin, S, Black, P, Petros, FG, Zargar, H, Dinney, CP, Cookson, MS, Kassouf, W, Dall'Era, MA, McGrath, JS, Wright, JL, Thorpe, AC, Morgan, TM, Holzbeierlein, JM, Bivalacqua, TJ, Sridhar, SS, North, S, Barocas, DA, Lotan, Y, Stephenson, AJ, van Rhijn, B, Spiess, PE, Daneshmand, S, Shariat, SF. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU international 127(5):528-537, 2021. e-Pub 2021. PMID: 32981193.
- Foerster B, Abufaraj M, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, Bandini M, Mathieu R, Ku JH, Marcq G, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, D'Andrea D, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Rouprêt M, Krabbe LM, Hendricksen K, Egawa S, Briganti A, Moschini M, Graffeille V, Kassouf W, Autorino R, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, Shariat SF. Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. Eur Urol. e-Pub 2021. PMID: 34023164.
- Abdelsalam ME, Sabir SH, Ba SBK, Karam JA, Matin SF, Wood CG, Ahrar K. Outcomes of Percutaneous Thermal Ablation for Biopsy-Proven T1a Renal Cell Carcinoma in Patients With Other Primary Malignancies. AJR Am J Roentgenol:1-7. e-Pub 2021. PMID: 33909469.
- Sharma V, Miest TS, Juvet TS, Toussi A, Packiam V, Chamie K, Matin SF, Boorjian SA, Thompson RH, Frank I, Tollefson MK, Potretzke AM. The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated meta-Analysis. J Urol:101097JU0000000000001834. e-Pub 2021. PMID: 33908802.
- Petros FG, Choi W, Qi Y, Moss T, Li R, Su X, Guo CC, Czerniak B, Dinney C, McConkey DJ, Matin SF. Expression Analysis of Same-Patient Metachronous and Synchronous Upper-Tract and Bladder Urothelial Carcinoma. J Urol:101097JU0000000000001788. e-Pub 2021. PMID: 33881933.
- Marcq G, Foerster B, Abufaraj M, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, Bandini M, Mathieu R, Ku JH, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, D'Andrea D, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Rouprêt M, Krabbe LM, Hendricksen K, Egawa S, Briganti A, Moschini M, Graffeille V, Autorino R, John P, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, Shariat SF, Kassouf W. Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. Eur Urol Focus. e-Pub 2021. PMID: 33773965.
Review Articles
- Pal, S, Grivas, PD, Gupta, S, Valderrama, BP, Rodriguez-Vida, A, Roghmann, F, Sevillano Fernandez, E, Matin, S, Loriot, Y, Sridhar, SS, Sonpavde, G, Fleming, MT, Lerner, SP, Bellmunt, J, Master, VA, Tripathi, A, Davis, K, van Veenhuyzen, D, Weng, R, Daneshmand, S. Infigratinib versus placebo in patients with resected urothelial cancer (UC) bearing FGFR3 mutation or fusion. Journal of Clinical Oncology 42:629, 2024. e-Pub 2024.
- Mertens LS, Sharma V, Matin SF, Boorjian SA, Houston Thompson R, van Rhijn BWG, Masson-Lecomte A. Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies. Eur Urol Open Sci 49:60-66, 2023. e-Pub 2023. PMID: 36793750.
- McIntosh AG, Umbreit EC, Wood CG, Matin SF, Karam JA. Role of lymph node dissection at the time of open or minimally invasive nephroureterectomy. Transl Androl Urol 10(5):2233-2245, 2021. e-Pub 2021. PMID: 34159106.
Other Articles
- Matin, S Matin discusses early work with FGFR inhibition in localized UTUC. Urology Times 52(6):22-23, 2024.
- Hensley PJ, Labbate CV, Matin SF Beyond the Abstract: Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Uro Onc Seminars 40(10):454, 2022.
- Labbate CV, Adibi M, Matin SF Editorial Comment. J Urol 207(6):1309-1310, 2022. PMID: 35236102.
Editorials
- Shapiro DD, Karam JA, Master VA, Sexton WJ, Matin SF, Spiess PE, Abel EJ. Re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.03.003. Eur Urol Oncol 6(6):638-639, 2023. PMID: 37268448.
- Shapiro DD, Karam JA, Master VA, Zemp LW, Sexton WJ, Matin SF, Spiess PE, Jason Abel E. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6. Eur Urol 84(2):e55-e56, 2023. PMID: 37149462.
- Westerman ME, Matin SF. EDITORIAL COMMENT. Urology 156:160-161, 2021. PMID: 34758553.
- Miest TS, Matin SF. Editorial Comment: Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration). J Urol:101097JU000000000000178602. PMID: 34105990.
- Sharma V, Miest TS, Juvet TS, Toussi A, Packiam V, Chamie K, Matin SF, Boorjian SA, Thompson RH, Frank I, Tollefson MK, Potretzke AM. Reply by Authors. J Urol:101097JU000000000000183402. PMID: 34121427.
Abstracts
- Das A, Shapiro D, Karam J, Master V, Spiess P, Raman J, Esdaille A, Zemp L, Sharma P, Sexton W, Patil D, Allen G, Matin S, Abel EJ. MP28-01: Cytoreductive Nephrectomy Perioperative Outcomes Have Significantly Improved in Recent Years. The Journal of Urology 209(4S):e369, 2023. e-Pub 2023.
- Shapiro D, Karam J, Master V, Spiess P, Raman J, Sexton W, Zemp L, Patil D, Lauer K, Allen G, Matin S, Abel EJ. PD24-01: The Selection for CytoREductivE Nephrectomy (SCREEN) Score: Surgical Risk Stratification Integrating Radiographic Features. The Journal of Urology 209(4S):e721, 2023. e-Pub 2023.
- Caceres JH, Egner T, Labbate C, Matin S, Nagpal S, Huang W, Persily J, Wettstein M, Choe J, Linehan J, Tachibana IT, Kaimakliotis H, Perecman A, Canes D, Raman J. MP58-20: Overall Survival after Endoscopic Treatment of UTUC. The Journal of Urology 209(4S):e804, 2023. e-Pub 2023.
- Hensley P, Labbate C, Xiao L, Zganjar A, Durdin T, Huelster H, Pham J, Howard J, Pallauf M, Lombardo K, Potretzke A, Spiess P, Raman J, Margulis V, Singla N, Coleman J, Matin S. MP69-11: Predictive Nomogram for Post-Nephroureterectomy GFR Estimation. The Journal of Urology 209(4S):e968, 2023. e-Pub 2023.
- Hara K, Corredor-Alonso GE, Serrano AG, Hernandez SD, Lu W, Shah AY, Jonasch E, Karam JA, Matin SF, Tannir NM, Msaouel P, Sircar K, Solis LM, Tang C. Evaluation of immune exhaustion across the evolution of oligometastatic clear cell renal cell carcinoma using spatially resolved tissue immune profiling: Secondary analysis of a prospective trial. Journal of Clinical Oncology 41(6):701, 2023. e-Pub 2023.
- Abdelsalam M, Awad A, Baiomy A, Karam J, Matin S, Ahrar K. 1-Long-term survival outcome radiofrequency ablation of biopsy proven T1a renal cell carcinoma (RCC). CIRSE 2022, 2022. e-Pub 2022.
- Abdelsalam M, Mecci N, Awad A, Lu T, Matin S, Karam J, Ahrar K. 2-The survival outcome of MRI guided cryoablation for biopsy proven T1a renal cell carcinoma (RCC). CIRSE 2022, 2022. e-Pub 2022.
- Hensley PJ, Miest T, Adibi M, Campbell M, Shah A, Cherry L, Papadopoulos J, Siefker-Radtke A, Gao J, Guo C, Czerniak B, Navai N, Kamat A, Dinney C, Matin SF. GFR fluctuation induced by neoadjuvant chemotherapy correlates with pathologic stage of upper tract urothelial carcinoma. Eur Uro 79(S1):S1090-S1091. e-Pub 2021.
- Abdelsalam M, Mecci N, Matin S, Wood C, Karam J, Ahrar K. Magnetic resonance imaging–guided cryoablation of de novo solitary pathologically proven T1a renal tumors. Journal of Vascular and Interventional Radiology 32(5):S165. e-Pub 2021.
- Hasanov E, Peterson CB, Matin SF, Wood CG, Sircar K, Tannir NM, Jonasch E. Hypoxia Signaling and Immune Infiltration in a Presurgical Trial of Sunitinib in Patients with Clear Cell Renal Cell Carcinoma (RCC). 2019 ASCO Annual Meeting.
- Gao JJ, Siefker-Radtke AO, Navai N, Campbell MT, Tidwell RS, Guo C, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Blando JM, Vence LM, Duan F, Basu S, Singh S, Zhao H, Allison JP, Dinney CP, Sharma P. A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC). 2019 ASCO Annual Meeting.
- Gao JJ, Karam JA, Tannir NM, Campbell MT, Tidwell RS, Ahrar K, Rao P, Ng CS, Jonasch E, Matin SF, Zurita AJ, Shah AY, Shen Y, Blando JM, Vence LM, Basu S, Zhao H, Allison JP, Wood CG, Sharma P. A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx). 2019 ASCO Annual Meeting.
- Geynisman DM, Kadow BT, Shuch BM, Boorjian SA, Matin SF, Rampersaud E, McClean D, Milestone BN, Plimack ER, Zibelman MR, Kutikov A, Smaldone MC, Chen D, Viterbo R, Joshi S, Greenberg RE, Malizzia L, McGowan T, Ross EA, Uzzo R. Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (SAGE). 2019 Genitourinary Cancers Symposium.
Book Chapters
- Narayan VM, Jayaratna IS, Matin SF, Pettaway CA. Robotic-Assisted Inguinal Lymphadenectomy. In: The Comprehensive Atlas of Robotic Urologic Surgery: A Step-by-Step Guide to Adult and Pediatric Urologic Procedures. Third. Springer, 399-404, 2025.
- Narayan, VM, Jayaratna, IS, Matin, S, Pettaway, CA. Robotic-Assisted Inguinal Lymphadenectomy, 399-404, 2025.
- Rogers CG, Matin SF. Renal Ischemia and Approach to the Renal Hilum in Robotic Partial Nephrectomy: Tips and Tricks. In: Robotic Surgery.
- Delacroix S, Matin SF, Wood CG. Kidney Cancer. In: M.D. Anderson Survival Monograph.
Letters to the Editor
- Pal SK, Grivas P, Gupta S, Dizman N, Zengin Z, Valderrama BP, Rodriguez-Vida A, Roghmann F, Sevillano Fernandez E, Matin SF, Loriot Y, Sridhar SS, Sonpavde G, Fleming MT, Lerner SP, Bellmunt J, Master V, Tripathi A, Davis K, van Veenhuyzen D, Weng R, Daneshmand S. Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration. Eur Urol 87: 271-274, 2025.
- Shanker, MD, Yu, ZH, Yang, J, Matin, S, Campbell, M, Msaouel, P, Tannir, NM, Prajapati, S, Ding, Y, Lee, B, Sobremonte, A, Tang, C. MR-Linac-guided stereotactic radiotherapy for CT-indiscernible intravascular renal cell carcinoma tumours. BJUI Compass 5: 913-915, 2024.
- Abel EJ, Master VA, Spiess PE, Raman JD, Shapiro DD, Sexton WJ, Zemp L, Patil D, Lauer K, Allen GO, Matin SF, Karam JA. Reply to Eduard Roussel, Riccardo Bertolo, Chiara Ciccarese, et al's Letter to the Editor re. Eur Urol Oncol 7: 302-303, 2024.
- Sharma V, Miest TS, Chamie K, Matin SF, Boorjian SA, Potretzke AM. The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-analysis. Reply. J Urol 206: 1072, 2021.
Patient Reviews
CV information above last modified February 06, 2026